Quanterix Corp (QTRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quanterix Announces Leadership Transition Plan Everett Cunningham Steps Down as President and CEO to Accept Another Opportunity Jim Gute, Quanterix’s Chief Commercial Officer, Appointed to the Additional Role of Interim President and CEO Board Has Initiated a Search
- Person
- Everett Cunningham
- Title
- President and Chief Executive Officer
- Action
- resigned
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The company reaffirmed its 2026 business outlook while appointing an interim CEO and initiating a search for a permanent replacement, signaling continuity but acknowledging a leadership reset.
Market read
This is a primary disclosure of an immediate CEO departure and interim appointment, which can drive near-term sentiment and positioning ahead of any further leadership or strategy updates.
What to watch
Investors may focus on whether the company’s reaffirmed 2026 outlook implies confidence in near-term execution despite the CEO change, and on any forthcoming details from the executive search process.
Background
Quanterix filed an 8-K for Item 5.02 and Regulation FD, detailing a leadership transition plan and compensatory arrangements tied to the CEO change.
Ticker impact
Quanterix announced Everett Cunningham stepped down as President and CEO, appointing Jim Gute as Interim CEO while it searches for a new CEO.
Likely choppy trading as investors price in transition risk and wait for details on the CEO search and any compensation or strategy changes.
The filing is a primary disclosure of an immediate CEO change and interim appointment, but it does not provide new financial guidance numbers beyond reaffirming the 2026 outlook.
Market effects
May increase attention on management stability across precision diagnostics and biomarker platforms, but no direct sector-wide policy or product catalyst is disclosed.
Limited regional spillover; this is company-specific leadership and governance news.
Global relevance is modest, as the event is an internal executive transition with no stated international regulatory or commercial contract impact.
Counterpoint
Interim CEO appointment from within the commercial leadership team could reduce disruption and support continuity in revenue execution while the board runs the search.
Key entities
- issuerQuanterix Corp
Precision biomarker science company filing the 8-K for CEO departure and interim CEO appointment.
- executiveEverett Cunningham
Stepped down as President and CEO and as a member of the board, effective immediately.
- executiveJim Gute
Chief Commercial Officer appointed Interim President and CEO while the board searches for a new CEO.
- governanceBoard of Directors
Initiated a search for a new CEO and engaged an executive search firm.


